

The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liabilities whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CK Life Sciences Int'l. (Holdings) Inc.

長江生命科技集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8222)

**RESULTS OF THE RIGHTS ISSUE OF 3,203,690,800 RIGHTS SHARES
AT HK\$0.65 PER RIGHTS SHARE IN THE PROPORTION OF ONE
RIGHTS SHARE FOR EVERY TWO EXISTING SHARES HELD ON
THE RECORD DATE PAYABLE IN FULL ON ACCEPTANCE**

The Directors announce that the Rights Issue had been oversubscribed and that as at 4:00 p.m. on Thursday, 4 May 2006, 4,666 valid acceptances had been received for a total of 3,114,391,667 Rights Shares provisionally allotted under the Rights Issue (representing approximately 97.21% of the total Rights Shares available for subscription) and 3,789 valid applications had been received for a total of 1,136,333,367 excess Rights Shares (representing approximately 35.47% of the total Rights Shares available for subscription). Accordingly, the Rights Issue was approximately 32.68% oversubscribed for a total of 4,250,725,034 Rights Shares.

All conditions to which the Rights Issue is subject have been fulfilled. Certificates in respect of the Rights Shares will be despatched to those entitled thereto at their own risk by ordinary post to their registered addresses on Friday, 12 May 2006. Dealings in the fully-paid Rights Shares will commence on Monday, 15 May 2006.

Reference is made to the prospectus in relation to the Rights Issue issued by the Company on 13 April 2006. Capitalised terms used in this announcement shall have the same meanings as those set out in the prospectus unless otherwise defined herein.

RESULTS OF THE RIGHTS ISSUE

The Directors announce that the Rights Issue was oversubscribed and that as at 4:00 p.m. on Thursday, 4 May 2006, being the latest time for acceptance of and payment for the Rights Shares and for application and payment for excess Rights Shares:–

- 4,666 valid acceptances of Rights Shares provisionally allotted had been received for a total of 3,114,391,667 Rights Shares (representing approximately 97.21% of the total Rights Shares available for subscription) (among which valid acceptances of 2,350,007,142 Rights Shares had been received from the Major Shareholders); and

- 3,789 valid applications for excess Rights Shares had been received for a total of 1,136,333,367 Rights Shares (representing approximately 35.47% of the total Rights Shares available for subscription) (among which valid applications for 200,792,857 Rights Shares in aggregate had been received from the Major Shareholders).

The Rights Shares accepted and paid for by the Major Shareholders under the provisional allotment of Rights Shares, amounting to approximately 73.35% of the total Rights Shares available for subscription, represent the number of Rights Shares which they had undertaken to accept under the Rights Issue. The Major Shareholders also applied for 200,792,857 excess Rights Shares in aggregate, and have been allotted in aggregate 14,372,857 excess Rights Shares representing approximately 0.45% of the total Rights Shares available for subscription. The aggregate percentage shareholdings of the Major Shareholders in the Company after the completion of the Rights Issue is approximately 73.50% of the total issued share capital of the Company as enlarged by the Rights Issue.

Based on the above subscription results of the Rights Issue, the Rights Issue was approximately 32.68% oversubscribed for a total of 4,250,725,034 Rights Shares.

EXCESS RIGHTS SHARES

The Directors have resolved to allot (from among the Rights Shares allotted provisionally but not accepted, the unsold fractional entitlements to the Rights Shares and the unsold Rights Shares to which the Non-Qualifying Shareholders would otherwise have been entitled) to each of the applicants such number of excess Rights Shares on the following basis:–

No. of excess Rights Shares applied for	No. of valid applications	Approximate percentage of allocation	Basis of allotment
1 to 4,000	2,179	100%	In full
4,220 to 120,415,714	1,609	7.16% to 66.66%	Including odd lot excess Rights Shares applied for in full and the remaining excess Rights Shares applied for at a pro rata percentage and rounded up to a board lot
590,576,699	1	7.08%	Approximately 7.08%

SHAREHOLDING STRUCTURE OF THE COMPANY

To the best knowledge of the Directors, the shareholding structure of the Company before and immediately after completion of the Rights Issue is as follows:

Shareholders	Number of Shares owned before completion of the Rights Issue		Number of Shares owned immediately after completion of the Rights Issue	
Gold Rainbow Int'l Limited	2,820,008,571	44.01%	4,238,634,570	44.10%
Trueway International Limited	1,410,004,286	22.01%	2,119,318,286	22.05%
Triluck Assets Limited	470,001,429	7.33%	706,441,429	7.35%
Certain Directors or their associates and a management shareholder	414,386,414	6.47%	421,486,414	4.39%
Sub-total	5,114,400,700	79.82%	7,485,880,699	77.89%
Public	1,292,980,900	20.18%	2,125,191,701	22.11%
Total	<u>6,407,381,600</u>	<u>100%</u>	<u>9,611,072,400</u>	<u>100%</u>

Upon completion of the Rights Issue, the number of Shares in the hands of the public is not below the prescribed minimum of 20% of the total issued Shares required to be in the hands of the public under the GEM Listing Rules.

GENERAL

All conditions to which the Rights Issue is subject have been fulfilled. Certificates in respect of the Rights Shares will be despatched to those entitled thereto at their own risk by ordinary post to their registered addresses on Friday, 12 May 2006. Dealings in the fully-paid Rights Shares will commence on Monday, 15 May 2006.

By order of the Board
CK Life Sciences Int'l., (Holdings) Inc.
Eirene Yeung
Company Secretary

Hong Kong, 10 May 2006

As at the date of this announcement, the Executive Directors of the Company are Mr. Li Tzar Kuoi, Victor (Chairman), Mr. Kam Hing Lam, Mr. Ip Tak Chuen, Edmond, Mr. Yu Ying Choi, Alan Abel, Dr. Pang Shiu Fun and Dr. Chu Kee Hung; and the Non-executive Directors are Mr. Peter Peace Tulloch, Professor Wong Yue-chim, Richard (Independent Non-executive Director), Mrs. Kwok Eva Lee (Independent Non-executive Director) and Mr. Colin Stevens Russel (Independent Non-executive Director).

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (i) the information contained in this announcement is accurate and complete in all material respects and is not misleading; (ii) there are no other matters the omission of which would make any statement in this announcement misleading; and (iii) all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.

The announcement will remain on the “Latest Company Announcements” page of the GEM website at www.hkgem.com for at least 7 days from the date of its posting and on the website of the Company at www.ck-lifesciences.com.